stockrowMedicus Pharma Ltd
MDCXHealthcare Drug Manufacturers General
- EPS
- +51.2%
- Free cash flow
- −27.7%
Quarter to June 2026, against a year earlier
Follow MDCX
Alert me
Medicus Pharma Ltd (MDCX) Return on invested capital
Medicus Pharma Ltd's return on invested capital over the twelve months to 30 June 2026 was −2,497.5%, down 2497.5 percentage points from fiscal 2025 (0.00%). That is below the Drug Manufacturers General industry median of 6.26% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | — |
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| GSK GSK PLC Sponsored ADR compare | 9.61% |
| OGN Organon & Co. compare | 6.26% |
| GRFS Grifols, S.A. compare | 4.76% |
| BIIB Biogen Inc. compare | 1.94% |
| NSRX Nasus Pharma Ltd. compare | 0.00% |
| SCLX Scilex Holding Company compare | 0.00% |
| AMRN Amarin Corporation PLC compare | −16.6% |
| MDCX Medicus Pharma Ltd | −2,497.5% |
| MIRA MIRA Pharmaceuticals, Inc. compare | −12,016.1% |
| Drug Manufacturers General industry median | 6.26% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)